Apopytosis and necrosis increase antigenicity of proteins recognized by antinuclear antibodies

Reumatismo

Volumn 56, Issue 3, 2004, Pages 156-161

  Herrera VanOostdam, D A ^a   Esparza Ibarra, E ^a   Ramirez Sandoval R ^a   Ortiz, V ^a   Bollain Y Goitia, J J ^a   Avalos Biaz, E ^a   Herrera Esparza, R ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE ZACATECAS   (Mexico)

^b NONE   (Mexico)

Author keywords

Antigen cleavage; Antinuclear antibodies; Apoptosis; Necrosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CAMPTOTHECIN; CELL ANTIGEN; CELL EXTRACT; MERCURIC CHLORIDE; PYROXYLIN; AUTOANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; TUMOR ANTIGEN; TUMOR PROTEIN;

ANTIBODY DETECTION; ANTIGEN BINDING; ANTIGENICITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA PROBE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN CELL; LUMINESCENCE; LUMINESCENT DOT ELISA SYSTEM; MOLECULAR RECOGNITION; NECROSIS; PROTEIN ANALYSIS; PROTEIN BINDING; SERODIAGNOSIS; STATISTICAL SIGNIFICANCE; ANTIGEN ANTIBODY REACTION; AUTOIMMUNE DISEASE; BLOOD; DIFFUSE SCLERODERMA; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; LARYNX TUMOR; MIXED CONNECTIVE TISSUE DISEASE; NICK END LABELING; PATHOLOGY; SJOEGREN SYNDROME; SQUAMOUS CELL CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; TUMOR CELL LINE;

ANTIBODIES, ANTINUCLEAR; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, NEOPLASM; APOPTOSIS; AUTOANTIGENS; AUTOIMMUNE DISEASES; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IN SITU NICK-END LABELING; LARYNGEAL NEOPLASMS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MERCURIC CHLORIDE; MIXED CONNECTIVE TISSUE DISEASE; NECROSIS; NEOPLASM PROTEINS; SCLERODERMA, DIFFUSE; SJOGREN'S SYNDROME;

EID: 4944244307     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Casciola-Rosen L, Anhalt GJ, Rosen A. Autoantigen targeted in systemic lupus erythematosus are clustered in two populations of surface blebs on cultured keratinocytes. J Exp Med 1994; 179: 1317-30.
2. Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR. Role of apoptosis in autoimmunity. Apoptosis 2000; 5: 443-9.
3. Vaishnaw AK, Orlinck JR, Chu J-L, Krammer PH, Chao MV, Elkon KB. Molecular basis for the apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 1999; 103: 355-63.
4. Mevorach D, Mascarenhas JO, Gershov D, Elkon K. Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 1998; 188: 2313-20.
5. Ogden CA, de Cathelianeau A, Hoffman PR, Bratton D, Ghebrehiwet B, Fadok VA, et al. Clq and mannose binding lectin engagement of cell surface calreticulin and CD91 iniciates macropinocytosis and uptake of apoptotic cells. J Exp Med 2001; 194: 781-96.
6. Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 2000; 405: 85-90.
7. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000; 192: 1353-64.
8. Bickerstaff MC, Botto, Hutchinson WL, Hebert J, Tennent GA, Bybee A, et al. Serum amiloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5: 694-7
9. Dijstelbloem HM, Bijl M, Fijnheer R, Scheepers RH, Oost WW, Jansen MD, et al. Fc gamma receptor polymorphysms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum 2000; 43: 2793-800.
10. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 127: 1-7.
11. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61: 554-8.
12. Valentini G, Bencivelli W, Bombardieri S, D'Angelo S, Della Rossa A, Silman AJ, Black CM, Czirjak L, Nielsen H, Vlachoyiannopoulos PG. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis. 2003; 62: 901-3.
13. Maddison PJ. Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol. 2000; 14: 111-24.
14. Rothenberg ML. Topoisomerase I inhibitors. Review and update. Ann Oncol 1997; 8: 837-55.
15. Goering PL, Thomas D, Rojko JL, Lucas AD. Mercuric chloride-induced apoptosis is dependent on protein synthesis. Toxicol Lett 1999; 105: 183-5.
16. Herrera Esparza R, Swaak T, Aarden L, Smeenk R. Complement-fixing antibodies to dsDNA detected by immunofluorescence technique on Crithidia luciliae. A critical appraisal. J Rheumatol 1985; 12: 1109-17.
17. Bijl M, Limburg PC, Kallenberg C. New inights into the pathogenesis of systemic lupus erythematosus (SLE): the role of apoptosis. Neth J Med 2001; 59: 66-75.
18. Rodenburg RJ, Raats JM, Pruijn GJ, van Venrooij WJ. Cell death: a trigger of autoimmunity. Bioessays 2000; 22: 627-36.
19. Degen WGJ, van Aarssen Y, Pruijn GJ, Utz PJ, Van Venroij WJ. The fate of U1 snRNP during anti-Fas induced apoptosis; specific cleavage of the U1 snRNA molecule. Cell Death Differ 2000; 7: 70-9.
20. Brockstedt E, Rickers A, Kostka S, Laubersheimer A, Dröken B, Wittmann-Liebold B, et al. Identification of apoptosis-associated proteins in human Burkitt lymphoma cell line. J Biol Chem 1998; 273: 28057-64.
21. Thiede B, Dimmler C, Siejak F, Rudel T. Predominant identification of RNA-binding proteins in Fas-induced apoptosis by proteome analysis. J Biol Chem 2000; 276: 26044-50.
22. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implication of autoimmunity. J Exp Med 1999; 190: 815-25.
23. Alarcon-Segovia D, Wakim KG, Worthington JW, Ward LE. Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus. Medicine (Baltimore) 1967; 46: 1-33.
24. Liebes L, Potmesil M, Kim T, Pease D, Buckley M, Fry D, et al. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res 1998; 4: 545-47.
25. Ayukawa K, Taniguchi S, Masumoto S, Hashimoto S, Savortam H, Kara A, et al. La autoantigen is cleaved in the COOH terminal and loses the nuclear localization signal during apoptosis. J Biol Chem 2000; 275: 34465-70.
26. Pollard KM, Pearson DL, Blüthner M, Tan E. Proteolytic cleavage of a self-antigen following xenobiotic-induced cell death produces a fragment with novel immunogenic properties. J Immunol 2000; 165: 2263-70.
27. Fritzler MJ. Autoantibodies: diagnostic fingerprints and etiologic perplexities. Clin Invest Med 1997; 20: 50-66
28. Du L, Fukushima S, Sallmyr A, Manthorpe R, Bredberg A. Exposure of HEp-2 cells to stress conditions influences antinuclear reactivity. Clin Diagn Lab Immunol 2002; 9: 287-94.
29. Fadok VA, de Cathelineau A, Daleke DL, Henson PM, Bratton DL. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem 2001; 276: 1071-7
30. Proskuryakov SY, Konoplyannikov AG, Gabai VL. Necrosis: a specific form of programmed cell death? Exp Cell Res 2003; 283: 1-16.
31. Wu X, Molinaro C, Johnson N, Casiano CA. Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity. Arthritis Rheum 2001; 44: 2642-52.
32. Ramirez-Sandoval R, Sanchez-Rodriguez S, Herrera-vanOstdam D, Avalos-Diaz E, Herrera-Esparza R. Antinuclear antibodies recognize cellular autoantigens driven by apoptosis. Joint Bone Spine 2003; 70: 187-94.